VONV vs XBI
Vanguard Russell 1000 Value ETF vs SPDR S&P Biotech ETF
- • VONV has the lower expense ratio at 0.06% vs 0.35% for XBI.
- • VONV pays a higher dividend yield (1.53%).
Side-by-side metrics
| Metric | VONV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.06% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.53% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $24.72B | $10.92B |
YTD return | 26.30% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.75 | 1.01 |
P/E ratio | 21.69 | — |
Last price | $115.49 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
VONV top holdings
| AMZN | Amazon.com Inc | 6.08% |
| AAPL | Apple Inc | 6.06% |
| MSFT | Microsoft Corp | 5.23% |
| BRK-B | Berkshire Hathaway Inc Class B | 2.55% |
| JPM | JPMorgan Chase & Co | 2.43% |
| XOM | ExxonMobil Holdings Corp | 1.84% |
| JNJ | Johnson & Johnson | 1.75% |
| INTC | Intel Corp | 1.51% |
| ABBV | AbbVie Inc | 1.17% |
| CSCO | Cisco Systems Inc | 1.17% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About VONV
VONV (Vanguard Russell 1000 Value ETF) is Vanguard's large-cap value ETF. Managed by Vanguard, the fund carries $24.7B in assets under management, an expense ratio of 0.06%, a dividend yield of 1.53%. Its largest holding is Amazon.com Inc (AMZN), which represents 6.1% of the portfolio. Real Estate is the fund's largest sector exposure at 3.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.